SEC Filing Summary: Leap Therapeutics, Inc. (10-Q)
Filing identity: The supplied filing is for Leap Therapeutics, Inc. (Nasdaq: LPTX), not CYPHERPUNK TECHNOLOGIES INC. It covers the quarter ended March 31, 2022; financial amounts below are in U.S. dollars unless stated otherwise.
Business context and reporting period
Leap is a clinical-stage biopharmaceutical company developing cancer therapies. Its lead candidate, DKN-01, is an investigational antibody targeting DKK1 and is being studied in several cancer indications. The company had no approved product and no product-sales revenue. BeiGene holds an option and license covering DKN-01 in Asia (excluding Japan), Australia, and New Zealand; Leap retains rights elsewhere.
Financial results and position
- Revenue: $0 in Q1 2022, versus $375,000 in Q1 2021. The prior-period license revenue was amortization of BeiGene’s upfront payment; it was fully recognized by year-end 2021.
- Expenses and loss: R&D expense was $7.784 million, up $977,000 year over year; G&A was $2.848 million, up $108,000. Operating loss was $10.632 million versus $9.172 million. Net loss was $10.376 million versus $9.134 million. Basic and diluted loss per share was $0.09 versus $0.12.
- R&D detail: DKN-01 spending rose to $7.740 million from $6.615 million; TRX518 spending declined to $44,000 from $192,000. R&D incentive income from Australia was $37,000 versus $71,000.
- Cash flow: Operating cash use was $11.518 million versus $8.587 million. Financing cash use was $210,000, primarily deferred offering costs. Cash and cash equivalents decreased by $11.696 million during the quarter.
- Liquidity and obligations: Cash and cash equivalents were $103.220 million at March 31, 2022, including $101.004 million in cash equivalents. Current assets were $104.944 million and current liabilities $7.344 million. Total liabilities were $7.344 million, including $363,000 of lease liabilities; the filing reports no conventional borrowing debt. The company said cash was expected to fund operating expenses for at least 12 months from issuance of the financial statements.
- Other balance-sheet items: Accumulated deficit was $273.948 million and stockholders’ equity was $98.557 million. No operating margin is meaningful given the absence of product revenue and ongoing losses.
Material changes versus the prior comparable period
- Net loss increased by $1.242 million, reflecting higher operating expenses and no BeiGene license revenue in Q1 2022; a $235,000 foreign-currency gain partly offset the loss, compared with a $21,000 loss in Q1 2021.
- R&D costs increased mainly from clinical-trial costs, higher R&D headcount and related compensation, and stock-based compensation; lower manufacturing costs partly offset these increases.
- Cash used in operations increased by $2.931 million. Cash at quarter-end was $103.220 million, compared with $43.491 million at March 31, 2021.
Outlook, development, and risks
- Management expected continued operating losses and said R&D spending would increase as development continued, subject to funding availability. The company may seek equity financing, government-program funding, collaborations, or licensing arrangements. Without additional funding or cost-sharing, it could delay, reduce, or eliminate trials and research programs.
- Management reported positive preliminary DisTinGuish Phase 2a results presented at the January 2022 ASCO GI symposium: among 25 evaluable first-line patients receiving a full cycle, reported overall response rate was 68.2%; preliminary median progression-free survival was 10.7 months, and median overall survival had not been reached. In the second-line DKK1-high group, reported response rate was 25% among 30 response-evaluable patients. These are clinical-trial findings, not proof of efficacy or regulatory approval.
- Enrollment in Part B of DisTinGuish was completed in May 2022, after the quarter. Leap also announced a companion-diagnostic development agreement with Leica Biosystems and planned to present initial DKN-01 prostate-cancer trial data at the June 2022 ASCO meeting.
- Key risks include clinical and regulatory uncertainty, trial enrollment or timing delays, manufacturing and funding needs, competition, and potential effects of COVID-19. DKN-01 remained investigational and had not been submitted to the FDA for approval. No material legal proceedings or material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- Confirm the issuer identity: the request names CYPHERPUNK TECHNOLOGIES INC., but the filing and financial statements identify Leap Therapeutics, Inc.
- Review the clinical-trial protocols, patient populations, analysis methods, and follow-up supporting the preliminary DKN-01 response and progression-free-survival results.
- Assess cash runway against ongoing trial, manufacturing, and other commitments; the filing disclosed $6.982 million of noncancelable manufacturing commitments and said runway was at least 12 months from issuance.
- Check the cash-flow discussion: its summary table labels periods “2021” and “2020,” although the financial statements and surrounding discussion identify the comparison as Q1 2022 and Q1 2021.
- Understand potential dilution: the filing reported 88.3 million issued and outstanding shares but 113.2 million weighted-average shares for EPS, including certain nominal-exercise-price warrants; additional options, RSUs, and warrants were excluded from diluted EPS as anti-dilutive.